View the current CareBareRX program options (official CareBareRX page) Content and Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment
On 29 April, 2022, FDA approved Camzyos (mavacamten) capsules to treat adults with symptomatic New York Heart Association (NYHA)External Link Disclaimer class II-III obstructive hypertrophic cardiomyopathy (oHCM) to improve exercise capacity and symptoms
Personalized Peptide Therapy for Women at Aesthetics MedSpa Peptides like BPC-157 offer remarkable healing properties, but theyre not a one-size-fits-all solution
Its a patient safety issue that regulators take extremely seriously
February 2024 IN THIS ISSUE FEATURE STORIES 2024 HEDIS Medical Record Project Provider Portal: New
Chen Wei C, Peishan Z, Wenbin, et al